An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
Authors:
- Timothy M MillerTMTimothy M Miller
- Alan PestronkAPAlan Pestronk
- William DavidWDWilliam David
- Jeffrey RothsteinJRJeffrey Rothstein
- Ericka SimpsonESEricka Simpson
- Stanley H AppelSAStanley H Appel
- Patricia L AndresPAPatricia L Andres
- Katy MahoneyKMKaty Mahoney
- Peggy AllredPAPeggy Allred
- Katie AlexanderKAKatie Alexander
- Lyle W OstrowLOLyle W Ostrow
- David SchoenfeldDSDavid Schoenfeld
Open Access
- 1 May 2013
- journal article
- research article
- Published by Elsevier in The Lancet Neurology
- Vol. 12 (5) , 435-442
Abstract
No abstract availableKeywords
Funding Information
- ALS Association
- Muscular Dystrophy Association
- National Institutes of Health (K08NS074194, R01NS078398)
- National Center for Advancing Translational Sciences
- Institute of Clinical and Translational Sciences (UL1 TR000448)
- National Institute of Neurological Disorders and Stroke
This publication has 22 references indexed in Scilit:
- Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin SynthesisNeuron, 2012
- Localization of a toxic form of superoxide dismutase 1 protein to pathologically affected tissues in familial ALSProceedings of the National Academy of Sciences, 2012
- Astrocytes from familial and sporadic ALS patients are toxic to motor neuronsNature Biotechnology, 2011
- Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular AtrophyScience Translational Medicine, 2011
- Targeted therapy for high-grade glioma with the TGF- 2 inhibitor trabedersen: results of a randomized and controlled phase IIb studyNeuro-Oncology, 2010
- Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALSNature Neuroscience, 2010
- Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review)Neurology, 2009
- Wild-type SOD1 overexpression accelerates disease onset of a G85R SOD1 mouseHuman Molecular Genetics, 2009
- Common molecular signature in SOD1 for both sporadic and familial amyotrophic lateral sclerosisProceedings of the National Academy of Sciences, 2007
- Antisense oligonucleotide therapy for neurodegenerative diseaseJournal of Clinical Investigation, 2006